Form 4: Amgen EVP David M. Reese Reports Stock Disposal for Tax Obligations

David M. Reese, EVP & Chief Technology Officer of Amgen, disposed of 6,202 shares of common stock on March 18, 2024, to cover tax obligations related to vested Restricted Stock Units.

Summary

• On March 18, 2024, David M. Reese, the EVP & Chief Technology Officer of Amgen, reported a transaction involving the disposal of 6,202 shares of Amgen common stock.
• The transaction was executed to satisfy tax obligations related to vested Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $268.87 per share.
• Following the transaction, Reese beneficially owns 60,666 shares of Amgen common stock, which includes unvested RSUs and Dividend Equivalents (DEs).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often related to compensation packages and tax planning. The disposal of shares to cover tax obligations is a routine practice.

Comparison to Industry Standards

• Executive compensation practices, including the use of RSUs and stock options, are standard across the pharmaceutical and biotechnology industries.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize equity-based compensation to align executive interests with shareholder value.
• The vesting schedules and terms of Amgen's RSUs appear consistent with industry norms for executive compensation packages.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, as it is a routine disposal of shares for tax purposes.

Key Dates